Thus, activating in-cell killing by anti-CD44 antibody that works together with either endogenous or infused exogenous NK cells may preferentially kill CSC for some types of cancers, reducing the frequency of relapse which warrants further investigation in the future. This evidence concerns the gene CD44 and cancer.